Indeed, brachytherapy offers numerous advantages over other treatment options. It is as efficient as other treatment options, has fewer side effects and is cost effective. Given these factors, sooner rather than later, brachytherapy will become the treatment of choice for early stage prostate cancer.
One of the most promising companies in the brachytherapy space is IsoRay Inc. (NYSEMKT: ISR), a Richland, Washington-based company engaged in the development, manufacture and sale of Cesium-131, a radioisotope used in brachytherapy.
ISR’s Cesium-131 has numerous advantages over other radioisotopes. It has superior energy and the shortest half-life, which makes it an effective treatment option not just for prostate cancer but also for other forms of aggressive cancer.
IsoRay’s sole focus over the past decade has been to increase awareness of Cesium-131 among the patient and the medical community. And it has been successful in this regard as evidenced by the company’s shares performance in 2014. Last year, ISR shares were among the top performers on the NYSEMKT, gaining more than 190%.
The gains came on the back of some successful peer-reviewed studies that highlighted the effectiveness of Cesium-131.
On Wednesday, ISR announced its financial results for the quarter ended December 31, 2014. At the end of the quarter, the company had $20 million in cash on its balance sheet and no debt. This is very unusual for an early-stage company like IsoRay. However, the financial situation highlights the astuteness of the management, which took advantage of the surge in stock price last year and completed a secondary offering.
Given ISR’s robust cash position and current burn rate, the company will not need any additional cash for at least the next five years. This completely takes out the dilution risk, which is usually associated with early stage companies like IsoRay.
On the operating front, the company has not been doing too badly either. It remains committed to diversifyi
So two more days and we are half way through February. Volume is dead. Am I the only one that is starting to doubt this big run this month? Would love to see the "explosion to 0.50-1.00." any day now. Just sayin. Thoughts on the dead silence, volume, lame news as of late? TIA